Lab test could personalize brain tumor treatment
NCT ID NCT06620380
First seen Jun 25, 2026 · Last updated Jun 30, 2026 · Updated 3 times
Summary
This study tests a lab technique called pharmacoscopy that quickly checks which drugs work best on a patient's own brain metastasis tissue. About 102 adults with brain metastases and few treatment options will have their tumor samples tested. The goal is to see if using this test to guide treatment improves survival compared to standard care.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Pharmacoscopy (a lab test to measure drug sensitivity on tumor samples)
- What this could lead to
- If successful, this approach could help doctors choose more effective treatments for brain metastases, especially when standard options are limited.
- What could go wrong
- This is a Phase 2 trial with only 102 participants, so results may not apply to everyone. The lab test may not always predict real-world drug response.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 102 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Sep 2025
- Expected to finish
-
Jun 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients must be 18 years or older on the day of signing the informed consent, female or male. * Patients must have a Karnofsky performance status of 60 or more * Patients must have limited systemic therapeutic options as per treating physician judgement. The number of previous lines of therapies is not limited. * Patients with a tumor with a targetable oncogenic driver mutation should have already been treated with a targeted agent and options must have been exhausted. * Patients must have a clinical indication for surgery for probable brain metastasis * Patients will be considered eligible for the study only if the diagnosis of brain metastasis has been histologically confirmed on the sample obtained during the surgery performed after signing the informed consent form for the trial. * Any type of primary cancer is allowed: breast cancer, lung cancer, melanoma, other cancers. Patients may have several primary cancers. * Patients must have adequate bone marrow, renal and hepatic function documented at screening before surgery * Women of childbearing potential, including women who had their last menstruation in the last 2 years, must have a negative urinary or serum pregnancy test * Patients must have the ability to understand the requirements of the study, provide written informed consent and authorization of use and disclosure of protected health information, and agree to abide by the study restrictions and return for the required assessments. * Written informed consent for study participation must be signed and dated by the patient and the investigator prior to any study-related intervention. Exclusion Criteria: * Patients with rapidly progressive systemic disease * Patients with inability to undergo brain MRI evaluation. * Patients with progressive parenchymal brain metastases with an indication for requiring whole brain radiotherapy after surgery. Focal brain radiotherapy after surgery is allowed. * Judgement by the investigator that the patient is unlikely to comply with study procedures, restrictions and requirements. * Intention to become pregnant during the course of the study. * Female who are pregnant. * Female who are breastfeeding and who do not agree to discontinue nursing prior to the first treatment initiated during the study. * Sexually active males and females of childbearing potential who are not willing to use an effective contraceptive method during the study. Male participants who do not agree not to donate sperm.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Brain metastases are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
3 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Cantonal Hospital St Gallen
NOT_YET_RECRUITINGSankt Gallen, Switzerland
-
University Hospital Basel
RECRUITINGBasel, Switzerland
-
University Hospital Zurich
RECRUITINGZurich, Switzerland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can doctors watch brain metastases instead of zapping them?
- Starving brain tumors of blood before surgery
- Tiny gadolinium particles aim to make brain radiation hit harder
- A sharper MRI could reveal radiation sensitivity of brain tumors
- Expert tumor board may extend survival in brain metastases
- Can a new pill outsmart lung cancer in the brain?